subscribeSubscribe
Hospira`s Biologic Nivestym (filgrastim-aafi) Receives Approval in the U.S.

Hospira`s Biologic Nivestym (filgrastim-aafi) Receives Approval in the U.S.
FDA
16 Feb 2024
Share Share
Sicor`s Biologic Granix (Tbo-filgrastim) Receives Approval in the U.S.

Sicor`s Biologic Granix (Tbo-filgrastim) Receives Approval in the U.S.
FDA
21 Nov 2023
Share Share
Kashiv BioSciences`s Biologic Releuko (Filgrastim) Receives Approval in the U.S.

Kashiv BioSciences`s Biologic Releuko (Filgrastim) Receives Approval in the U.S.
FDA
01 Sep 2023
Share Share
Aurobindo`s subsidiary to withdraw mkt authorization for EU 2 biosimilar

Aurobindo`s subsidiary to withdraw mkt authorization for EU 2 biosimilar
INDIANPHARMAPOST
25 Jun 2023
Share Share
Kashiv`s Biologic Releuko (Filgrastim) Receives Approval in the U.S.

Kashiv`s Biologic Releuko (Filgrastim) Receives Approval in the U.S.
FDA
28 Oct 2022
Share Share
Kashiv Bio Bags Approval for Its First Biosimilar RELEUKOTM (filgrastim-ayow)

Kashiv Bio Bags Approval for Its First Biosimilar RELEUKOTM (filgrastim-ayow)
BUSINESSWIRE
02 Mar 2022
Share Share
Amneal Enters U.S. Biosimilars Market With Approval of RELEUKOTM

Amneal Enters U.S. Biosimilars Market With Approval of RELEUKOTM
BUSINESSWIRE
01 Mar 2022
Share Share
Kashiv Biosciences` Biologic Releuko (Filgrastim) Receives Approval in the U.S.

Kashiv Biosciences` Biologic Releuko (Filgrastim) Receives Approval in the U.S.
FDA
25 Feb 2022
Share Share
Tanvex drug approved for marketing in Canada

Tanvex drug approved for marketing in Canada
Kao Shih-ching TAIPEITIMES
18 Oct 2021
Share Share
Canadian Cancer Patients Have New Affordable Treatment Option

Canadian Cancer Patients Have New Affordable Treatment Option
NEWSWIRE
27 Sep 2021
Share Share